Abstract: The present invention provides vectors that contain and co-express in vivo or in vitro immunogenic polypeptides or antigens together with an OX40L polypeptide, which functions as a genetic adjuvant. Together, the immunogenic polypeptide and the OX40L polypeptide elicit an immune response in animal or human, which is greater than the immune response elicited by the immunogenic polypeptide alone.
Type:
Application
Filed:
January 19, 2017
Publication date:
May 18, 2017
Applicant:
MERIAL, INC.
Inventors:
Teshome Mebatsion, Jules Maarten Minke, Frederic David
Abstract: The disclosure relates to a spray applicator system for accurately and precisely dosing liquid formulations, including vaccines and probiotic formulations, to caged avian animals. In particular, the disclosure relates to spray applicators, having improved acceptance by the avian animals, relative to more disruptive prior spray applicators. The disclosed automated caged spray applicator system is designed to attach to and function with automated poultry feeding systems, routinely used in poultry house settings.
Type:
Application
Filed:
October 13, 2016
Publication date:
May 4, 2017
Applicant:
MERIAL INC.
Inventors:
Christopher Davis Leslie, Francisco Javier Rojo Barrañón, Hector Valdemar Garcia Espinosa
Abstract: This disclosure provides attenuated swine influenza strains, particularly those produced via a reverse genetics approach, compositions comprising same, and methods of production and use thereof. The attenuated strains are engineered to encode HA proteins having additional glycosylation sites, relative to the HA proteins encoded by the corresponding virulent parental viruses. Advantageously, the attenuated influenza strains may be administered.
Abstract: The present invention relates to novel anthelmintic compounds of formula (I) below: wherein Y and Z are independently a bicyclic carbocyclic or a bicyclic heterocyclic group, or one of Y or Z is a bicyclic carbocyclic or a bicyclic heterocyclic group and the other of Y or Z is alkyl, alkenyl, alkynyl, cycloalkyl, phenyl, heterocyclyl or heteroaryl, and variables X1, X6, X8, Q1, Q2, Q3, Q4, Q5, Q6, Ring A, Ring B, W, W?, R2, R3, R, R?, m, n and q are as defined herein. The invention also provides for veterinary compositions comprising the anthelmintic compounds of the invention, and their uses for the treatment and prevention of parasitic infections in animals.
Abstract: The present invention encompasses engineered Newcastle Disease Virus (NDV) vaccines or compositions. The vaccine or composition may be a recombinant vaccine. The invention also encompasses recombinant vectors encoding and expressing avian pathogen antigens, more specifically avian influenza proteins, epitopes or immunogens. Such vaccines or compositions can be used to protect animals, in particular avian, against disease.
Type:
Grant
Filed:
May 2, 2014
Date of Patent:
April 11, 2017
Assignee:
MERIAL, INC.
Inventors:
Michel Bublot, Frederic Reynard, François-Xavier Le Gros
Abstract: The present invention encompasses canine parvovirus (CPV) vaccines or compositions. The vaccine or composition may be a vaccine or composition containing CPV virus-like particle (VLP), and a preparation method and a use thereof. The CPV VLPs provided by the invention are formed by the CPV VP2 protein. Further, the invention broadly encompasses vaccines comprising combinations of MLV and VLP, which are capable of overcoming MDA against a variety of pathogens, which infect a variety of different species.
Abstract: The present invention relates generally to the fields of immunology and vaccine technology. More specifically, the present invention relates to methods for freeze-drying biological preparations, including peptides, antigens, antibodies, and especially, cells. Importantly, the disclosed methods preserve the viability, infectivity and immunogenicity of cells from the Apicomplexa phylum, the Sarcocystidae family, and in particular, cells from the Toxoplasma genus.
Type:
Application
Filed:
May 13, 2015
Publication date:
March 30, 2017
Applicants:
MERIAL INC., VITAMFERO S.A, L'Universite De Bourgogne, L'Institut National Superieur des Sciences Agronom iques de L'Alimentation et de L'Environment
Inventors:
Noel Yves Henri Jean Genin, Jean-Christophe Audonnet, Didier Roy, Edouard Seche, Patrick Gervais, Samira Khaldi-Plassart, Romain Useo, Joelle DeConinck
Abstract: The present invention provides vectors that contain and express in vivo or in vitro one or more Hendra virus polypeptides or antigens that elicit an immune response in animal or human against Hendra virus and Nipah virus, compositions comprising said vectors and/or Hendra virus polypeptides, methods of vaccination against Hendra virus and Nipah virus, and kits for use with such methods and compositions.
Abstract: The present invention encompasses vaccines or compositions comprising the chimeric KSAC protein that possesses immunogenic and protective properties, and methods of use including administering to an animal the antigenic KSAC protein thereof to protect animals. The invention also encompasses methods for making and producing the soluble, disaggregated, refolded or active proteins from inclusion bodies produced from prokaryotes or eukaryotes.
Type:
Application
Filed:
February 5, 2016
Publication date:
March 23, 2017
Applicant:
MERIAL INC.
Inventors:
Laurent Bernard Fischer, Nicolas Pierre Yves Carboulec, Fabien Lux
Abstract: This disclosure provides attenuated Histophilus somni strains, compositions comprising same, and methods of production and use thereof. The attenuated strains may express lower or no levels of various virulence-associated genes, relative to the corresponding pathogenic bacteria Advantageously, the attenuated Histophilus somni strains may be administered orally, intranasally, intra-tracheally, or subcutaneously.
Type:
Grant
Filed:
March 25, 2015
Date of Patent:
March 14, 2017
Assignee:
MERIAL, INC.
Inventors:
Tammy Kolander, Paulraj Lawrence, Russell Bey
Abstract: The following discloses mammalian cells lines that stably express functional nematode acetylcholine receptor subunits. The resulting expression of functional ion channels has been made possible by the stable co-expression of the chaperone protein, RIC3. These cell lines are extremely useful for the high throughput screening (HTS) of compounds, to identify new candidate parasiticidal, including nematocidal, active ingredients.
Type:
Application
Filed:
September 9, 2015
Publication date:
March 9, 2017
Applicants:
MERIAL, INC., SANOFI
Inventors:
Lance Hammerland, Brenda Bondesen, Jean-Marie Chambard, Thierry Vermat, Werner Dittrich, Michel Partiseti, Qing Zhou-Liu, Cathy Cojean, Rachid Boukaiba, Eric Tagat
Abstract: The present invention provides vectors that contain and co-express in vivo or in vitro immunogenic polypeptides or antigens together with an OX40L polypeptide, which functions as a genetic adjuvant. Together, the immunogenic polypeptide and the OX40L polypeptide elicit an immune response in animal or human, which is greater than the immune response elicited by the immunogenic polypeptide alone. In a particular example, the invention provides vectors encoding a Rabies G immunogenic polypeptide and a canine OX40L genetic adjuvant, which vectors elicit strong immune responses in canine against rabies virus.
Type:
Grant
Filed:
February 14, 2013
Date of Patent:
February 14, 2017
Assignee:
MERIAL INC.
Inventors:
Teshome Mebatsion, Jules Maarten Minke, Frederic David
Abstract: The present invention provides uses of aryl alkyl malononitrile compounds of formula (I), or veterinarily acceptable salts thereof, for controlling and preventing parasite infestations in animals. The invention also provides methods for controlling and preventing parasite infestation in animals comprising administering an effective amount of at least one aryl alkyl malononitrile compound of formulae (I), or a veterinarily acceptable salt thereof, to the animal.
Type:
Application
Filed:
April 17, 2015
Publication date:
February 2, 2017
Applicants:
MERIAL INC., BASF, SE
Inventors:
Charles Meng, Christian Miculka, Mark Soll, Ralph Paulini, Matthias Pohlman, Sebastian Sorgel, Henricus Maria Martinus Bastiaans, Sarah Thompson, Cecille Ebuenga Doyog, Anna Malveda Umali, Rhoel Suiza Cosare, Christopher Palmer, Takeo Hokama
Abstract: This disclosure provides an attenuated palmiped parvovirus that affords heterologous protection for both Muscovy duck parvovirus and goose parvovirus (i.e., Derzsy's Disease). The disclosure further provides compositions comprising the same, and methods of production and use thereof.
Abstract: The present invention relates to compositions comprising replication defective Schmallenberg virus vaccines, methods of producing the vaccines, and the administration of such vaccines to animals, including ovines and bovines. The invention further relates to methods for providing long-term protective immunity against Schmallenberg in animals, including ovines and bovines.
Abstract: The invention relates to an intraruminal sustained release capsule which is capable of delivering a sustained release dose of a first medicament to an animal, as well as either or both of a dump dose of a second medicament or mineral, and an exit dose of a third medicament or mineral. The capsule can have a dissolvable overcap molded from plasticized starch enabling a dump dose of medicament to be held between the overcap and one end of the capsule. A piston within the body of the capsule can be modified to enable it to accommodate an exit dose of medicament within its hollow interior which is aligned with an aperture at the end of the capsule which enables release of the medicaments to the rumen. After insertion of the capsule in the animal the overcap (if present) dissolves and separates from the capsule to release the dump dose of medicament. The sustained release medicament is then dispensed via the apertured end, followed by the release of the exit dose of medicament (if present).
Abstract: The present invention provides recombinant herpesvirus of turkeys (HVT) vectors that contain and express antigens of avian pathogens, compositions comprising the recombinant HVT vectors, polyvalent vaccines comprising the recombinant HVT vectors and one or more wild type viruses or recombinant vectors. The present invention further provides methods of vaccination against a variety of avian pathogens and method of producing the recombinant HVT vectors.
Type:
Grant
Filed:
June 23, 2015
Date of Patent:
January 31, 2017
Assignee:
MERIAL, INC.
Inventors:
Michel Bublot, Teshome Mebatsion, Joyce Pritchard, Perry Linz
Abstract: The present invention provides compositions or vaccines that contain a recombinant EHV-1 that elicit an immune response in animals against equine herpesvirus, including compositions comprising the recombinant EHV-1, methods of vaccination against equine herpesvirus, and kits for use with such methods and compositions.
Type:
Grant
Filed:
November 17, 2014
Date of Patent:
January 31, 2017
Assignee:
Merial, Inc.
Inventors:
Jean Christophe Audonnet, Jules Maarten Minke, Nikolaus Osterrieder, Guanggang Ma
Abstract: The present invention provides cyclic depsipeptide compounds of formula (I) and compositions comprising the compounds that are effective against parasites that harm animals. The compounds and compositions may be used for combating parasites in or on mammals and birds. The invention also provides for an improved method for eradicating, controlling and preventing parasite infestation in birds and mammals.
Type:
Application
Filed:
May 20, 2016
Publication date:
January 26, 2017
Applicant:
MERIAL INC.
Inventors:
Loic Le Hir de Fallois, Greg Pacofsky, Alan Long, Charles Meng, Hyoung Ik Lee, Cyprian O. Ogbu